Ferrari E, Maffeo D A, Graziano R, Gallo M S, Pignata S, De Rosa L, Montella M, Pergola M
Divisione di Oncologia Medica B., Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale, Napoli.
Eur J Gynaecol Oncol. 1994;15(6):437-42.
Twenty-five patients with Stage III ovarian cancer were entered into a trial with intraperitoneal combinations of carboplatin (400 mg/cqm) and recombinant interferon alfa (50 MU). All patients had received prior intravenous platinum-based chemotherapy and underwent 2nd look laparotomy at study entry. Our study indicates that this combination chemotherapy is safely administered by the intraperitoneal route. Myelotoxicity was frequent, but rarely of grade 3. No major local toxicity was recorded by accessing the peritoneal cavity with a temporary catheter. The response to treatment was promising in the group of patients with less then 2 cm residual disease at study entry (15 patients); in this group, all patients had no clinical evidence of disease at the completion of the therapy. In 2 cases reexploration was performed and pCR was recorded. Only one patient of this group relapsed during a mean follow-up of 21 months. Two pCRS were also recorded in the group of patients with more than 2 cm at 2nd look (9 patients), although relapse occurred after 9 and 15 months respectively. In the remaining patients of this group, persistence of disease was observed after intraperitoneal chemotherapy.
25例III期卵巢癌患者进入一项关于卡铂（400mg/cqm）与重组干扰素α（50MU）腹腔联合用药的试验。所有患者此前均接受过静脉铂类化疗，并在研究开始时接受了二次探查剖腹术。我们的研究表明，这种联合化疗通过腹腔途径给药是安全的。骨髓毒性很常见，但很少达到3级。通过临时导管进入腹腔未记录到严重局部毒性。对于研究开始时残留病灶小于2cm的患者组（15例患者），治疗反应良好；在该组中，所有患者在治疗结束时均无疾病临床证据。2例患者进行了再次探查并记录到病理完全缓解（pCR）。该组仅1例患者在平均21个月的随访期间复发。在二次探查时残留病灶大于2cm的患者组（9例患者）中也记录到2例pCR，尽管分别在9个月和15个月后出现复发。在该组其余患者中，腹腔化疗后观察到疾病持续存在。
